BML Investment Partners, L.P. 13D and 13G filings for Atea Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-12-16 09:50 am Purchase | 2024-12-13 | 13D | Atea Pharmaceuticals, Inc. AVIR | BML Investment Partners, L.P. | 7,216,312 8.500% | 1,614,233 (+28.81%) | Filing |
| 2024-02-07 09:25 am Unchanged | 2023-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR | BML Investment Partners, L.P. | 5,602,079 6.700% | 0 (Unchanged) | Filing |
| 2024-02-07 09:14 am Purchase | 2023-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR | BML Investment Partners, L.P. | 5,602,079 6.700% | 1,418,434 (+33.90%) | Filing |
| 2023-10-02 11:45 am Purchase | 2023-09-25 | 13G | Atea Pharmaceuticals, Inc. AVIR | BML Investment Partners, L.P. | 4,183,645 5.000% | 4,183,645 (New Position) | Filing |